

5

1. A three-dimensional model selected from the group consisting of: (a) a three-dimensional model of a human IgE Fc region comprising Cε3 and Cε4 domains (Fc-Cε3/Cε4), wherein said model substantially represents the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3;

10 and (b) a three-dimensional model comprising a modification of said model of (a),  
wherein said modification represents an antibody Fc region that binds to a FcεRIα  
protein.

2. A method to produce the three-dimensional model of Claim 1, wherein the three-dimensional model represents the Fc-C $\epsilon$ 3/C $\epsilon$ 4 region of a human IgE antibody, said method comprising representing amino acids of said region at substantially the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3.

3. A method to produce a three-dimensional model of a FcεRIα binding domain other than a human FcεRIα binding domain represented by the three-dimensional model substantially representing the atomic coordinates specified in Claim 1, said method comprising homology modeling.

- 5
4. An isolated crystal of a Fc-C $\epsilon$ 3/C $\epsilon$ 4 region of a human IgE antibody.
  5. A method to produce the isolated crystal of Claim 4, said method comprising vapor diffusion.

POSTED: 9/12/2006

- 5           6.       An isolated Fc-C $\epsilon$ 3/C $\epsilon$ 4 protein selected from the group consisting of: (a)  
a protein consisting of SEQ ID NO:2; and (b) a homologous protein that is structurally  
homologous to a protein of (a), wherein said homologous protein binds to a Fc $\epsilon$ RI $\alpha$   
protein.
7.       A nucleic acid molecule comprising a nucleic acid sequence that encodes  
10   said isolated Fc-C $\epsilon$ 3/C $\epsilon$ 4 protein of Claim 6.
8.       A recombinant molecule comprising the nucleic acid sequence of Claim 7.
9.       A recombinant virus comprising the nucleic acid sequence of Claim 7.
10.      A recombinant cell comprising the nucleic acid sequence of Claim 7.
11.      A method to produce a protein comprising culturing the recombinant cell  
15   of Claim 10.

FOIA b 7 - DATED 03/15/04

- 5           12.     A method to identify a compound that inhibits the binding between an IgE antibody and a FcεRIα protein, said method comprising using a three-dimensional model of a Fc-Cε3/Cε4 region of a human IgE to identify said compound, wherein said model substantially represents the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3.
- 10           13.     An inhibitory compound identified in accordance with the method of Claim 12.
14.     A therapeutic composition comprising the inhibitory compound of Claim 13.
15.     A method to protect an animal from allergy, said method comprising
- 15     administering to said animal the inhibitory compound of Claim 13.

TOSTE0-91260660

5           16.     A method to improve a function of an antibody comprising a Fc-Cε3/Cε4 region, said improved function being selected from the group consisting of increased stability, increased affinity for an IgE binding domain of a FcεRIα protein, altered substrate specificity, and increased solubility, said method comprising:

                  (a)     analyzing a three-dimensional model substantially representing the  
10           atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3 to identify at least one amino acid of the Fc-Cε3/Cε4 region represented by said model which if replaced by said identified amino acid(s) improves at least one of said functions of said Fc-Cε3/Cε4 region;  
                  and

15                   (b)     replacing said identified amino acid(s) to produce a mutein having at least one of said improved functions.

                  17.     A mutein produced by the method of Claim 16, wherein said mutein has an improved function compared to a Fc-Cε3/Cε4 protein comprising amino acid sequence SEQ ID NO:2, wherein said improved function is selected from the group consisting  
20           increased stability compared to the stability of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, increased affinity for a FcεRIα protein compared to the FcεRIα affinity of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, altered substrate affinity compared to the affinity for human FcεRIα of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, and increased solubility compared  
25           to the solubility of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2.

09809746-034504  
TOTAL 912660

- 5           18.     A polypeptide selected from the group consisting of a FcεRIα binding domain, an interdomain groove between the two Cε3/Cε4 domains of said antibody Fc region, a hinge between Cε3 and Cε4 domains of said antibody Fc region, and a region of a Cε3 or Cε4 domain, the relative position of which changes by greater than 1 angstrom between closed and receptor-bound Fc-Cε3/Cε4 conformations.
- 10           19.     The polypeptide of Claim 18, wherein said composition is selected from the group consisting of a linker between Cε2 and Cε3, a BC loop of Cε3, a DE loop of Cε3, and a FG loop of Cε3, a loop or strand defining the interdomain groove, a AB helix of Cε3 and, a region lying above said AB helix of Cε3.
20.     An isolated nucleic acid molecule encoding the polypeptide of Claim 18.

FILED: 2024-03-27